Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA

Abstract

The ability to study nonhematologic cancers through noninvasive sampling of blood is one of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven both by major technologic advances, including the isolation of intact cancer cells and the analysis of cancer cell-derived DNA from blood samples, and by the increasing application of molecularly driven therapeutics, which rely on such accurate and timely measurements of critical biomarkers. Moreover, the dramatic efficacy of these potent cancer therapies drives the selection for additional genetic changes as tumors acquire drug resistance, necessitating repeated sampling of cancer cells to adjust therapy in response to tumor evolution. Together, these advanced noninvasive diagnostic capabilities and their applications in guiding precision cancer therapies are poised to change the ways in which we select and monitor cancer treatments.

Significance: Recent advances in technologies to analyze circulating tumor cells and circulating tumor DNA are setting the stage for real-time, noninvasive monitoring of cancer and providing novel insights into cancer evolution, invasion, and metastasis.

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

D.A. Haber has received commercial research support from Johnson & Johnson and is a consultant/advisory board member of Life Technologies. V.E. Velculescu is member of the Board of Directors of Personal Genome Diagnostics and has ownership interest (including patents) in the same.

©2014 American Association for Cancer Research.

Figures

Figure 1

Clinical applications of CTC and ctDNA analyses in cancer care. The molecular analyses that are enabled by the isolation of CTCs and ctDNA from blood specimens are illustrated. These may be applied to guide different treatment strategies at different events in the initial diagnosis and treatment of patients with cancer.